Hi guys. Obviously great results today.
Can anyone shed some light on the potential cost for this treatment? Also manufacturing complexity etc... These are all equally important as the survival rate, as it seems like a therapy that would be difficult to roll out in the millions of doses.
- Forums
- ASX - By Stock
- MSB
- Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-227
-
- There are more pages in this discussion • 621 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B |
Open | High | Low | Value | Volume |
$1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 94863 | $1.13 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.13 | 5000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 85863 | 1.125 |
3 | 60500 | 1.120 |
3 | 49858 | 1.115 |
10 | 234700 | 1.110 |
3 | 20500 | 1.105 |
Price($) | Vol. | No. |
---|---|---|
1.130 | 1000 | 1 |
1.135 | 15000 | 2 |
1.140 | 10000 | 1 |
1.150 | 27892 | 3 |
1.155 | 25000 | 1 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |